Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans

Guide for the Care and Use of Laboratory Animals: Eighth Edition

(2011) · doi:10.17226/12910 · Cited by 16,199 · see citing works

Untitled work

(2000) · PubMed · Cited by 13,173 · see citing works

Guide for the care and use of laboratory animals

(1997) · Choice Reviews Online · doi:10.5860/choice.34-3310 · Cited by 2,930 · see citing works

Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies

Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238 · see citing works

The Fibroblast Growth Factor signaling pathway

Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050 · see citing works

Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction

Elumalai, A., & Jain, S. K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061321 · Cited by 1,172 · see citing works

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · see citing works

Fibroblast Growth Factor 21 Corrects Obesity in Mice

Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · see citing works

Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans

Zhang, X., Yeung, D. C. Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L. C., Chow, W.-S., Tso, A. W. K., Lam, K. S. L., et al. (2008) · Diabetes · doi:10.2337/db07-1476 · Cited by 908 · see citing works

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · see citing works

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21

Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · see citing works

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · see citing works

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550 · see citing works

An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice

Holland, W., Adams, A., Brozinick, J., Bui, H., Miyauchi, Y., Kusminski, C., Bauer, S., Wade, M., Singhal, E., Cheng, C. C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.019 · Cited by 525 · see citing works

FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss

Owen, B. M., Ding, X., Morgan, D. A., Coate, K. C., Bookout, A. L., Rahmouni, K., Kliewer, S. A., & Mangelsdorf, D. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.012 · Cited by 523 · see citing works

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500 · see citing works

A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects

Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B. M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.001 · Cited by 496 · see citing works

Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117)

Clarke, T.-K., Adams, M. J., Davies, G., Howard, D. M., Hall, L. S., Padmanabhan, S., Murray, A. D., Smith, B. H., Campbell, A., Hayward, C., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.153 · Cited by 440 · see citing works

Identification of Individuals With Insulin Resistance Using Routine Clinical Measurements

Stern, S. E., Williams, K., Ferrannini, E., DeFronzo, R. A., Bogardus, C., & Stern, M. P. (2005) · Diabetes · doi:10.2337/diabetes.54.2.333 · Cited by 384 · see citing works

FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver

von Holstein-Rathlou, S., BonDurant, L. D., Peltekian, L., Naber, M. C., Yin, T. C., Claflin, K. E., Urizar, A. I., Madsen, A. N., Ratner, C., Holst, B., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.003 · Cited by 347 · see citing works

FGF21 Regulates Sweet and Alcohol Preference

Talukdar, S., Owen, B. M., Song, P., Hernandez, G., Zhang, Y., Zhou, Y., Scott, W. T., Paratala, B., Turner, T., Smith, A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.008 · Cited by 342 · see citing works

FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms

BonDurant, L. D., Ameka, M., Naber, M. C., Markan, K. R., Idiga, S. O., Acevedo, M. R., Walsh, S. A., Ornitz, D. M., & Potthoff, M. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.005 · Cited by 330 · see citing works

A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21

Kliewer, S. A., & Mangelsdorf, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.004 · Cited by 273 · see citing works

FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia

Lan, T., Morgan, D. A., Rahmouni, K., Sonoda, J., Fu, X., Burgess, S. C., Holland, W. L., Kliewer, S. A., & Mangelsdorf, D. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.005 · Cited by 261 · see citing works

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity · doi:10.1002/oby.22344 · Cited by 257 · cited 2× · see citing works

<i>KLB</i> is associated with alcohol drinking, and its gene product β-Klotho is necessary for FGF21 regulation of alcohol preference

Schumann, G., Liu, C., O’Reilly, P., Gao, H., Song, P., Xu, B., Ruggeri, B., Amin, N., Jia, T., Preis, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611243113 · Cited by 241 · see citing works

Fructose ingestion acutely stimulates circulating FGF21 levels in humans

Dushay, J. R., Toschi, E., Mitten, E. K., Fisher, F. M., Herman, M. A., & Maratos-Flier, E. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.008 · Cited by 233 · see citing works

Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake

Tanaka, T., Ngwa, J. S., van Rooij, F. J., Zillikens, M. C., Wojczynski, M. K., Frazier-Wood, A. C., Houston, D. K., Kanoni, S., Lemaitre, R. N., Luan, J., et al. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.052183 · Cited by 226 · see citing works

FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans

Søberg, S., Sandholt, C. H., Jespersen, N. Z., Toft, U., Madsen, A. L., von Holstein-Rathlou, S., Grevengoed, T. J., Christensen, K. B., Bredie, W. L. P., Potthoff, M. J., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.009 · Cited by 216 · cited 1× · see citing works

Novel locus including FGF21 is associated with dietary macronutrient intake

Chu, A. Y., Workalemahu, T., Paynter, N. P., Rose, L. M., Giulianini, F., Tanaka, T., Ngwa, J. S., Qi, Q., Curhan, G. C., Rimm, E. B., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt032 · Cited by 195 · see citing works

Circadian Rhythm of Circulating Fibroblast Growth Factor 21 Is Related to Diurnal Changes in Fatty Acids in Humans

Yu, H., Xia, F., Lam, K. S., Wang, Y., Bao, Y., Zhang, J., Gu, Y., Zhou, P., Lu, J., Jia, W., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155184 · Cited by 170 · see citing works

LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys

Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065763 · Cited by 169 · see citing works

FGF21 Signals to Glutamatergic Neurons in the Ventromedial Hypothalamus to Suppress Carbohydrate Intake

Jensen-Cody, S. O., Flippo, K. H., Claflin, K. E., Yavuz, Y., Sapouckey, S. A., Walters, G. C., Usachev, Y. M., Atasoy, D., Gillum, M. P., & Potthoff, M. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.008 · Cited by 166 · see citing works

Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21

Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158 · see citing works

Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys

Véniant, M. M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., Zhou, L., Wada, R., Hecht, R. I., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2012-1211 · Cited by 147 · see citing works

FGF21 Is an Exocrine Pancreas Secretagogue

Coate, K. C., Hernandez, G., Thorne, C. A., Sun, S., Le, T. D. V., Vale, K., Kliewer, S. A., & Mangelsdorf, D. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.004 · Cited by 136 · see citing works

Circulating FGF21 proteolytic processing mediated by fibroblast activation protein

Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., & Gutierrez, J. A. (2016) · Biochemical Journal · doi:10.1042/bj20151085 · Cited by 123 · see citing works

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex

Kolumam, G., Chen, M. Z., Tong, R., Zavala-Solorio, J., Kates, L., van Bruggen, N., Ross, J., Wyatt, S. K., Gandham, V. D., Carano, R. A. D., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.05.028 · Cited by 108 · see citing works

FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases

Sonoda, J., Chen, M. Z., & Baruch, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0002 · Cited by 106 · see citing works

Human FGF-21 Is a Substrate of Fibroblast Activation Protein

Coppage, A. L., Heard, K. R., DiMare, M. T., Liu, Y., Wu, W., Lai, J. H.-S., & Bachovchin, W. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151269 · Cited by 71 · see citing works

Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans

Kralisch, S., Tönjes, A., Krause, K., Richter, J., Lössner, U., Kovacs, P. L., Ebert, T., Blüher, M., Stümvoll, M., & Faßhauer, M. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0367 · Cited by 65 · see citing works

FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes

Chen, M. Z., Chang, J. C., Zavala-Solorio, J., Kates, L., Thai, M., Ogasawara, A., Bai, X., Flanagan, S., Nunez, V., Phamluong, K., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.003 · Cited by 58 · see citing works

Downstream Signaling Pathways in Mouse Adipose Tissues Following Acute In Vivo Administration of Fibroblast Growth Factor 21

Muise, E. S., Souza, S., Chi, A., Tan, Y., Zhao, X., Liu, F., Dallas-yang, Q., Wu, M., Sarr, T., Zhu, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073011 · Cited by 57 · see citing works

Functional validity, role, and implications of heavy alcohol consumption genetic loci

Thompson, A., Cook, J. P., Choquet, H., Jorgenson, E., Yin, J., Kinnunen, T. K., Barclay, J. W., Morris, A. P., & Pirmohamed, M. (2020) · Science Advances · doi:10.1126/sciadv.aay5034 · Cited by 57 · see citing works

PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates

Thompson, W. C., Zhou, Y., Talukdar, S., & Musante, C. J. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9481-1 · Cited by 49 · see citing works

炭水化物摂取を抑制する腹内側視床下部におけるグルタミン酸作動性ニューロンへのFGF21シグナル【JST・京大機械翻訳】

Sharon, O., Kyle, H. F., Kristin, E. C., Yavuz, Y., Sarah, A. S., Grant, C., Yuriy, M. U., Atasoy, D., Matthew, P., & Matthew, J. P. (2020) · Cell Metabolism · Cited by 15 · see citing works

Whole transcriptome analysis and validation of metabolic pathways in subcutaneous adipose tissues during FGF21-induced weight loss in non-human primates

Murray, S. A., Dalbøge, L. S., Baquero, K., Sanford, C. A., Misquith, A., Mercer, A. J., Meek, T. H., Guldbrandt, M., Andersen, B., Kievit, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64170-6 · Cited by 12 · see citing works

Trends in insulin resistance: insights into mechanisms and therapeutic strategy

Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939 · see citing works

Bispecific Antibodies: From Research to Clinical Application

Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 310 · see citing works

Metabolic messengers: FGF21

Flippo, K. H., & Potthoff, M. J. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00354-2 · Cited by 311 · see citing works

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 193 · see citing works

Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease

Fraile, J. M., Palliyil, S., Barelle, C. J., Porter, A. J., & Kovaleva, M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s315724 · Cited by 152 · see citing works

FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance

Szczepańska, E., & Gietka‐Czernel, M. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1778-4159 · Cited by 155 · see citing works

New developments in the biology of fibroblast growth factors

Ornitz, D. M., & Itoh, N. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1549 · Cited by 143 · see citing works

The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application

Zhang, D., Zhang, Y., & Sun, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012572 · Cited by 102 · see citing works

The role of FGF21 and its analogs on liver associated diseases

Falamarzi, K., Malekpour, M., Tafti, M. F., Azarpira, N., Behboodi, M., & Zarei, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.967375 · Cited by 94 · see citing works

FGF19 and FGF21: In NASH we trust

Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 82 · see citing works

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

Sanyal, A. J., Ling, L., Beuers, U. H., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Hirschfield, G. M. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100255 · Cited by 80 · see citing works

Brown Adipose Tissue Heterogeneity, Energy Metabolism, and Beyond

Shinde, A. B., Song, A., & Wang, Q. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.651763 · Cited by 80 · see citing works

The potential function and clinical application of FGF21 in metabolic diseases

Chen, Z., Yang, L., Liu, Y., Huang, P., Song, H., & Zheng, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1089214 · Cited by 72 · see citing works

Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications

Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71 · see citing works

The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model

Spann, R. A., Morrison, C. D., & den Hartigh, L. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802541 · Cited by 75 · see citing works

Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho

Aaldijk, A. S., Verzijl, C. R. C., Jonker, J. W., & Struik, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1150222 · Cited by 63 · see citing works

Newly discovered endocrine functions of the liver

Rhyu, J., & Yu, R. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1611 · Cited by 62 · see citing works

The state of the art in secondary pharmacology and its impact on the safety of new medicines

Brennan, R., Jenkinson, S. G., Brown, A. J., Delaunois, A. G., Dumotier, B. M., Pannirselvam, M., Rao, M., Ribeiro, L. R., Schmidt, F., Sibony, A., et al. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00942-3 · Cited by 57 · see citing works

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

Александровна, П. В., Bezborodkina, N. N., & Okovityi, S. V. (2022) · Biomedicines · doi:10.3390/biomedicines10020274 · Cited by 52 · see citing works

Adipokines as Clinically Relevant Therapeutic Targets in Obesity

Würfel, M., Blüher, M., Stümvoll, M., Ebert, T., Kovacs, P. L., Tönjes, A., & Breitfeld, J. (2023) · Biomedicines · doi:10.3390/biomedicines11051427 · Cited by 54 · see citing works

Multi-organ FGF21-FGFR1 signaling in metabolic health and disease

Kaur, N., Gare, S. R., Shen, J., Raja, R., Fonseka, O., & Liu, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.962561 · Cited by 49 · see citing works

FGF21 signaling in glutamatergic neurons is required for weight loss associated with dietary protein dilution

Flippo, K. H., Jensen-Cody, S. O., Claflin, K. E., & Potthoff, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-76593-2 · Cited by 49 · see citing works

FGF-based drug discovery: advances and challenges

Chen, G., Chen, L., Li, X., & Mohammadi, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01125-w · Cited by 51 · see citing works

Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Loomba, R. S., Kowdley, K. V., Rodriguez, J., Kim, N. J., Alvarez, A. M., Morrow, L., Jeglinski, B. I., Clawson, A., Chowdhury, S. K., Bain, G., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00067-6 · Cited by 47 · see citing works

Hepatic hormone FGF21 and its analogues in clinical trials

Shao, W., & Jin, T. (2021) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.08.005 · Cited by 46 · see citing works

Bridging systemic metabolic dysfunction and Alzheimer’s disease: the liver interface

Song, D., Yang, L., Yang, L.-L., Luo, Y., & Yao, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00849-6 · Cited by 53 · see citing works

Pharmacological Support for the Treatment of Obesity—Present and Future

Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 48 · see citing works

Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics

Zhong, X., & D’Antona, A. M. (2021) · Antibodies · doi:10.3390/antib10020013 · Cited by 45 · see citing works

The secretory function of adipose tissues in metabolic regulation

Liu, Y., Qian, S., Tang, Y., & Tang, Q. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae003 · Cited by 48 · see citing works

FGF21 and Chronic Kidney Disease.

Salgado, J., Goes, M. A., & Salgado, N. (2021) · Metabolism: Clinical and Experimental · doi:10.1016/j.metabol.2021.154738 · Cited by 35 · see citing works

Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies

Hua, S., Liu, Q., Li, J., Fan, M., Yan, K., & Ye, D. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09661-1 · Cited by 39 · see citing works

Liver Brain Interactions: Focus on FGF21 a Systematic Review

Prida, E., Álvarez-Delgado, S., Pérez-Lois, R., Soto-Tielas, M., Estany‐Gestal, A., Fernø, J., Seoane, L. M., Quiñones, M., & Al–Massadi, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113318 · Cited by 39 · see citing works

Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network

Li, S., Zou, T., Chen, J., Li, J., & You, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.033 · Cited by 37 · see citing works

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis

Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 39 · see citing works

Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial

Wong, C., Dash, A., Fredrickson, J. O., Lewin‐Koh, N., Chen, S., Yoshida, K. J., Liu, Y., Gutierrez, J., & Kunder, R. S. (2022) · Hepatology · doi:10.1002/hep.32742 · Cited by 35 · see citing works

Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules

Prashanth, G., Vastrad, B. M., Tengli, A., Vastrad, C. M., & Kotturshetti, I. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00718-5 · Cited by 37 · see citing works

The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers

Rosenstock, M., Tseng, L., Pierce, A. A., Offman, E., Chen, C.-Y., Charlton, R., Margalit, M., & Mansbach, H. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001618 · Cited by 31 · see citing works

The Same Metabolic Response to FGF21 Administration in Male and Female Obese Mice Is Accompanied by Sex-Specific Changes in Adipose Tissue Gene Expression

En, M., Kazantseva, A. Y., Dubinina, A., Jakovleva, T., Balybina, N., Baranov, K. O., & Бажан, Н. М. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910561 · Cited by 33 · see citing works

Immunotherapeutic progress and application of bispecific antibody in cancer

Kang, J., Sun, T., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020003 · Cited by 34 · see citing works

Harnessing tissue-specific genetic variation to dissect putative causal pathways between body mass index and cardiometabolic phenotypes

Leyden, G. M., Shapland, C. Y., Smith, G. D., Sanderson, E. C. M., Greenwood, M. P., Murphy, D., & Richardson, T. G. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.12.013 · Cited by 27 · see citing works

CRISPRa‐based activation of Fgf21 and Fndc5 ameliorates obesity by promoting adipocytes browning

Zhu, H., Liu, D., Sui, M., Zhou, M., Wang, B., Qi, Q., Wang, T., Zhang, G., Wan, F., & Zhang, B. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1326 · Cited by 25 · see citing works

Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective

Zhang, Y., Wang, Y., & Liu, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.011 · Cited by 24 · see citing works

Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention

Mao, T., Sun, Y., Xu, X., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000234 · Cited by 24 · see citing works

Unlocking the potential of bispecific ADCs for targeted cancer therapy

Zeng, H., Ning, W., Liu, X., Luo, W., & Xia, N. (2024) · Frontiers of Medicine · doi:10.1007/s11684-024-1072-8 · Cited by 23 · see citing works

Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update

Huisman, T. M., Dieterich, D. T., & Friedman, S. L. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265286 · Cited by 23 · see citing works

Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders

Okuma, H., & Tsuchiya, K. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108699 · Cited by 22 · see citing works

Fibroblast growth factor 21: A “rheostat” for metabolic regulation?

She, Q.-Y., Bao, J., Wang, H.-Z., Liang, H., Huang, W., Wu, J., Zhong, Y.-W., Ling, H., Li, A., & Qin, S.-L. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155166 · Cited by 22 · see citing works

Hypoxia as a Double-Edged Sword to Combat Obesity and Comorbidities

Wang, R., Sun, Q., Wu, X., Zhang, Y., Xing, X., Lin, K., Feng, Y., Wang, M., Wang, M., & Wang, Y. (2022) · Cells · doi:10.3390/cells11233735 · Cited by 22 · see citing works

Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats

Tillman, E. J., Brock, W. J., & Rolph, T. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15725 · Cited by 22 · see citing works

Fibroblast Growth Factor 21 (FGF21) Administration Sex-Specifically Affects Blood Insulin Levels and Liver Steatosis in Obese Ay Mice

En, M., Kazantseva, A. Y., Dubinina, A., Denisova, E. I., Jakovleva, T., Balybina, N., Bgatova, N. P., Baranov, K. O., & Бажан, Н. М. (2021) · Cells · doi:10.3390/cells10123440 · Cited by 20 · see citing works

Emerging roles of brain tanycytes in regulating blood–hypothalamus barrier plasticity and energy homeostasis

Kannangara, H. S., Cullen, L., Miyashita, S., Korkmaz, F., Macdonald, A., Gumerova, A. A., Witztum, R., Moldavski, O., Sims, S. L., Burgess, J., et al. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15009 · Cited by 20 · see citing works

The Effect of FGF21 and Its Genetic Variants on Food and Drug Cravings, Adipokines and Metabolic Traits

Epperlein, S., Gebhardt, C., Rohde, K., Chakaroun, R., Patt, M., Schamarek, I., Kralisch, S., Heiker, J. T., Scholz, M. R., Stümvoll, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9040345 · Cited by 16 · see citing works

Single Nucleotide Polymorphisms in Close Proximity to the Fibroblast Growth Factor 21 (FGF21) Gene Found to Be Associated with Sugar Intake in a Swedish Population

Janzi, S., González-Padilla, E., Najafi, K., Ramne, S., Ahlqvist, E., Borné, Y., & Sonestedt, E. (2021) · Nutrients · doi:10.3390/nu13113954 · Cited by 14 · see citing works

Resting energy metabolism and sweet taste preference during the menstrual cycle in healthy women

Malo‐Vintimilla, L., Aguirre, C. A., Vergara, A., Fernández‐Verdejo, R., & Galgani, J. E. (2023) · British Journal Of Nutrition · doi:10.1017/s0007114523001927 · Cited by 17 · see citing works

Fibroblast growth factor 21

Trusz, G. J. (2024) · Differentiation · doi:10.1016/j.diff.2024.100793 · Cited by 15 · see citing works

Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids

Fiorenza, M., Checa, A., Sandsdal, R. M., Jensen, S. B. K., Juhl, C. R., Noer, M. H., Bogh, N. P., Lundgren, J. R., Janus, C., Stallknecht, B. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101629 · Cited by 14 · see citing works

A long‐acting FGF21 attenuates metabolic dysfunction‐associated steatohepatitis‐related fibrosis by modulating NR4A1‐mediated Ly6C phenotypic switch in macrophages

Ji, Y. R., Duan, Y., Li, Y., Lu, Q., Liu, D., Yang, Y., Chang, R., Jing, T., Yao, W., Yin, J., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16378 · Cited by 14 · see citing works

Fibroblast growth factor 21 and dietary macronutrient intake in female mice

Wu, C.-T., Larson, K. R., Goodson, M. L., & Ryan, K. K. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113995 · Cited by 11 · see citing works

New Mediators in the Crosstalk between Different Adipose Tissues

Gómez‐Hernández, A., Heras, N. D. L., Gálvez, B. G., Fernández‐Marcelo, T., Fernández‐Millán, E., & Escribano, Ó. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094659 · Cited by 12 · see citing works

β-Klotho as novel therapeutic target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A narrative review

Meroni, M., Dongiovanni, P., Tiano, F., Piciotti, R., Alisi, A., & Panera, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117608 · Cited by 13 · see citing works

Dietary protein restriction diminishes sucrose reward and reduces sucrose-evoked mesolimbic dopamine signaling in mice

Wu, C.-T., Magaña, D. G., Roshgadol, J., Tian, L., & Ryan, K. K. (2024) · Appetite · doi:10.1016/j.appet.2024.107673 · Cited by 11 · see citing works

Distinct genetic signals at the FGF21 locus complicate studies of FGF21's role in diet regulation using human cohort data

Ramne, S., García‐Ureña, M., Gillum, M. P., Ängquist, L. H., Hansen, T., Merino, J., & Grarup, N. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102049 · Cited by 11 · see citing works

Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next

Jin, T. (2022) · Medical Review · doi:10.1515/mr-2022-0019 · Cited by 8 · see citing works

Thrifty energy phenotype predicts weight regain in postmenopausal women with overweight or obesity and is related to FGFR1 signaling

Spranger, L., Weiner, J. M., Bredow, J., Zeitz, U., Grittner, U., Boschmann, M., Dickmann, S., Stobäus, N., von Schwartzenberg, R. J., Brachs, M., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.02.020 · Cited by 8 · see citing works

Defective FGFR1 Signaling Disrupts Glucose Regulation: Evidence From Humans With FGFR1 Mutations

Stamou, M. I., Chiu, C. J., Jadhav, S. V., Lopes, V. F., Salnikov, K. B., Plummer, L., Lippincott, M. F., Lee, H., Seminara, S. B., & Balasubramanian, R. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae118 · Cited by 7 · see citing works

Fibroblast growth factor-21 improves insulin action in nonlactating ewes

Lamb, C. L., Giesy, S. L., McGuckin, M. M., Perfield, J. W., Butterfield, A. M., Moniruzzaman, M., Haughey, N. J., McFadden, J. W., & Boisclair, Y. R. (2022) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00259.2021 · Cited by 7 · see citing works

Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr−/−.Leiden mice

Inia, J. A., Attema, J., de Ruiter, C., Menke, A. L., Caspers, M. P. M., Verschuren, L., Wilson, M. E., Arlantico, A., Brightbill, H. D., Jukema, J. W., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202401397r · Cited by 5 · see citing works

Investigation of the Characteristics of Crimean Congo Hemorrhagic Fever Cases Reported in Afyonkarahisar Province

Korkmaz, D., Konya, P. Ş., & Demirtürk, N. (2022) · Turkish Journal of Parasitology · doi:10.4274/tpd.galenos.2022.14633 · Cited by 5 · see citing works

Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach

Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 6 · see citing works

Saponins from Panax japonicus Enhance Lipolysis via Acting on FGF21-β-Klotho/FGFR1 in Obese Mice

Wang, T., Huang, Y., Hu, M., Huang, X., Yu, D., Jia, L., Zhi, W., Mu, Y., Zhou, Z., & Wang, J. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c01012 · Cited by 4 · see citing works

Hormones that are involved in metabolic homeostasis: Overview of the past century and future perspectives

Feng, J. N., & Jin, T. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100422 · Cited by 4 · see citing works

Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021

She, Q.-Y., Li, L., Liu, M.-H., Tan, R.-Y., Zhong, Y.-W., Bao, J., & Xie, J.-D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1011008 · Cited by 9 · see citing works

Identification of candidate nsSNPs of the human FNDC5 gene and their structural and functional consequences using in silico analysis

Majeed, S., Moin, H., Waseem, M., Khalid, Z., Abbasi, S. W., & Rasool, K. (2025) · Scientific Reports · doi:10.1038/s41598-024-83254-1 · Cited by 3 · see citing works

Identifying genetic variants associated with sugar intake and appraising the genetic correlations with cardiovascular outcomes

Janzi, S., Ramne, S., Kou, M., Lu, X., Stubbendorff, A., Ke, C., Borné, Y., Qi, L., & Sonestedt, E. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.08.020 · Cited by 2 · see citing works

Impaired Fibroblast Growth Factor 21 (FGF21) Associated with Visceral Adiposity Leads to Insulin Resistance: The Core Defect in Diabetes Mellitus

Jain, U., Srivastava, P., Sharma, A., Sinha, S., & Johari, S. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998265915231116043813 · Cited by 3 · see citing works

Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine

Romantsova, T. I. (2024) · Obesity and metabolism · doi:10.14341/omet13184 · Cited by 2 · see citing works

Novel Endocrine Signaling Axis in Cardiovascular‐Kidney‐Metabolic Syndrome: Interactions and Therapeutic Potential of FGF21 and GDF15

Yang, C., Chen, L., Xiao, H., Wei, W., Liang, J., Chen, T., Yang, T., & Ma, Y. (2026) · Journal of Cellular Biochemistry · doi:10.1002/jcb.70113 · Cited by 1 · see citing works

Fibroblast Growth Factor 21: Possible Role in Growth and Metabolic Development during Early Life, Nutritional Interactions and Biological Actions

Wali, J. A., Ramos-Nieves, J. M., Binia, A., & van der Beek, E. M. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100713 · Cited by 1 · see citing works

AAV2-mediated ABD-FGF21 gene delivery produces a sustained anti-hyperglycemic effect in type 2 diabetic mouse

Lu, S.-L., Pan, Z., Cui, Z. G., Wang, J., Yang, J., Lv, Y., Cao, C., & Huang, X. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123344 · Cited by 1 · see citing works

Gene Therapy for Diabetes

Jiménez, V., & Bosch, F. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch78 · Cited by 1 · see citing works

Dietary protein restriction diminishes sucrose reward and reduces sucrose-evoked mesolimbic dopamine signalingPreprint

Wu, C.-T., Magaña, D. G., Roshgadol, J., Tian, L., & Ryan, K. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.21.600074 · Cited by 1 · see citing works

Analytical Characterization of Bispecific Antibodies and Bispecific Molecules

Dillon, M. A., Lombana, T. N., & Spiess, C. (2025) · doi:10.1002/9781394236145.ch2 · Cited by 1 · see citing works

Community Series - Liver Fibrosis and MAFLD: from Molecular Aspects to Novel Pharmacological Strategies, Volume II

(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0

Pharmacological Effects of Fibroblast Growth Factor 21 (FGF21) оn Carbohydrate-Lipid Metabolism: Sex Dependence

Бажан, Н. М., & En, M. (2023) · Успехи физиологических наук · doi:10.31857/s0301179823040033

Correlations of Anthropometric and Body Composition Parameters with Fibroblast Growth Factor-21 Gene Expression in Peripheral Blood Mononuclear Cells of Healthy Young Adults

Mirhoseini, M., Eslamian, G., Ghorbani, A., Zand, H., & Vasheghani‐Farahani, E. (2024) · Iṭṭilā’āt-i māhiyānah. · doi:10.61186/nsft.19.2.1

Protein phosphatase 6 as an important downstream target of fibroblast growth 21 and its therapeutic analogues in attenuating MASH development

Feng, J. N., Tong, Q., & Jin, T. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100602

Kardiyokinlerin Obezite ve Beslenme İle İlişkisi

Gerboğa, R., & Yılmaz, H. Ö. (2025) · Sağlık Bilimleri ve Klinik Araştırmaları Dergisi · doi:10.63695/jhscr.1601578

Impact of D-Allulose on Sugar Craving and Obesity Prevention

Matsui, S. (2025) · Bulletin of Applied Glycoscience · doi:10.5458/bag.15.2_115

Insulin-sensitizing effects of fibroblast growth factor-21 in underfed sheep

dos Santos, A. C. R., McGuckin, M. M., Giesy, S. L., & Boisclair, Y. R. (2025) · Journal of Animal Science · doi:10.1093/jas/skaf217

Accurate quantification of anti-drug antibodies against each unique Fab of a bispecific antibody using an ECL bridging assay

Rowe, B., Reese, K. J., McGrath, K., Concannon, A. A., Schwartz, A. M., & Gunn, G. R. (2025) · Bioanalysis · doi:10.1080/17576180.2026.2617254

Agonistic bispecific antibodies: an emerging frontier in antibody therapeutics

Yang, J., Deng, J., Sun, Z., Liu, Y., Wang, Y., Meng, X. M., Liu, X., Ma, X. Y., & Sun, P. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08684-z

Alcohol, but not acetate, induces FGF21 in humans without association with subsequent food choice

Ramne, S., Dragsted, L. O., Dinjens, V., Magkos, F., Gillum, M. P., & Cuparencu, C. (2026) · The Journal of Nutritional Physiology · doi:10.1016/j.jnphys.2026.100048

Allosteric β-Klotho Modulation to Restore FGF21 Sensitivity in Type 2 DiabetesPreprint

Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-10986278/v1

Phase 2 study of fazpilodemab, a FGFR1/Klothoβ agonist, in metabolic dysfunction-associated steatohepatitis (MASH)

Sanyal, A. J., Zou, Y., Zhang, L., Dash, A., Fredrickson, J. O., Gutierrez, J., Yoshida, K., Liu, Y., Kunder, R. S., Wilson, M. E., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102068

Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging

Salmón‐Gómez, L., Keipert, S., Catalán, V., Rodrı́guez, A., Becerril, S., Frühbeck, G., & Gómez‐Ambrosi, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00627-w

Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex

Foltz, I. N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., Weiszmann, J., Stevens, J., Chen, J. S., Nuanmanee, N., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004690 · Cited by 211 · see citing works

Overexpression of β-Klotho in Adipose Tissue Sensitizes Male Mice to Endogenous FGF21 and Provides Protection From Diet-Induced Obesity

Samms, R. J., Cheng, C. C., Kharitonenkov, A., Gimeno, R. E., & Adams, A. C. (2016) · Endocrinology · doi:10.1210/en.2015-1722 · Cited by 73 · see citing works

Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds

Pérez‐Martí, A., Sandoval, V., Marrero, P. F., Haro, D., & Relat, J. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0034 · Cited by 24 · see citing works

The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic

Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607 · see citing works

FGF21 Can Be Mimicked In Vitro and In Vivo by a Novel Anti-FGFR1c/β-Klotho Bispecific Protein

Smith, R. J., Duguay, A. N., Bakker, A., Li, P., Weiszmann, J., Thomas, M. R., Alba, B. M., Wu, X., Gupte, J., Li, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061432 · Cited by 59 · see citing works